CRESTOR Demonstrates Dramatic CV Risk Reduction In A Large Statin Outcomes Study

New data from the JUPITER study demonstrated that CRESTOR(R)
(rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV)
events (defined in this study as the combined risk of myocardial infarction,
stroke, arterial revascularization, hospitalization for unstable angina, or
death from CV causes) by a dramatic 44% compared to placebo (p










Rosuvastatin 20 mg was well tolerated in nearly 9,000 patients
during the course of the study. There was no difference between treatment
groups for major adverse events, including cancer or myopathy. There was a
small increase in physician reported diabetes consistent with data from other
large placebo controlled statin trials.





About JUPITER





JUPITER (Justification for the Use of statins in Primary
prevention: an Intervention Trial Evaluating Rosuvastatin) was a long-term,
randomized, double-blind, placebo-controlled, large-scale study of 17,802
patients designed to determine if rosuvastatin 20 mg decreases the risk of
heart attack, stroke and other major cardiovascular events in patients with
low to normal LDL-C but at increased cardiovascular risk as identified by
elevated high-sensitivity C-reactive protein (hsCRP) and age. The majority of
patients had at least one other risk factor including hypertension, low
HDL-C, family history of premature coronary heart disease (CHD) or smoking.
hsCRP is a recognized marker of inflammation which is associated with an
increased risk of atherosclerotic cardiovascular events.





JUPITER is a part of AstraZeneca's extensive GALAXY clinical trials
programme, designed to address important unanswered questions in statin
research. Currently, more than 69,000 patients have been recruited from 55
countries worldwide to participate in the GALAXY Programme.




About CRESTOR (ROSUVASTATIN)





Studies have previously shown that CRESTOR was the most effective statin
at lowering LDL-C, had a significant effect on raising HDL-C and slowed the
progression of atherosclerosis, an underlying cause of cardiovascular
disease.





CRESTOR has now received regulatory approval in over 95 countries. Nearly
15 million patients have been prescribed CRESTOR worldwide. Data from
clinical trials and real world use shows that the safety profile for CRESTOR
is in line with other marketed statins.





About AstraZeneca





AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of $29.55
billion and leading positions in sales of gastrointestinal, cardiovascular,
neuroscience, respiratory, oncology and infection products. AstraZeneca is
listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4
Good Index.





This press release has been made available on worldwide press
communication media for the benefit of correspondents writing for the medical
professional press. Differing national legislation, codes of practice,
medical practice etc mean that you should contact your local AZ press office
to obtain information designed for use in your country.



Astrazeneca


View drug information on Crestor.